Aimed Alliance has released new recommendations for reforming the federal 340B Drug Pricing Program and advancing state-based alternatives to strengthen…
On August 14, Aimed Alliance submitted a comment to the Senate Finance Committee’s Request for Information on Commonsense Policy Options…
A new Yale University study raises questions about how the Trump Administration’s proposed Medicare international reference pricing (IRP) models, GLOBE…
On August 27, 2026, Aimed Alliance submitted feedback on Senator Cassidy’s 340B Drug Pricing Integrity and Affordability for Patients Act…
Aimed Alliance released three new patient-centered resources as part of its Patients & PDABs: Ensuring a Voice in the Process…
The 2026 Open Enrollment period is fast approaching! The 2026 Open Enrollment period for Medicare Advantage plans is October 15,…
Aimed Alliance sent a letter to Colorado Representative Ken DeGraaf regarding his special session bill, “Prescription Drug Benefit Information Transparency” (HB25B-1012).…
On October 3, the Colorado Prescription Drug Affordability Board (PDAB) voted to establish an upper payment limit (UPL) for Enbrel,…
On October 7, 2025, Aimed Alliance sent a follow-up letter to the U.S. Food and Drug Administration (FDA) regarding the…
Aimed Alliance submitted a comment to the Oregon Prescription Drug Affordability Board (PDAB) urging it to maintain a careful, evidence-based…